Cargando…

High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia

We determined lymphoid enhancer-binding factor-1 (LEF1) mRNA expression in 112 chronic lymphocytic leukemia (CLL) samples and assessed correlations with the prognostic markers ZAP70 and CD38, Binet stages, the percentage of lymphocytes in the peripheral blood, and fibromodulin (FMOD) transcripts. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdfelder, Felix, Hertweck, Magdalena, Filipovich, Alexandra, Uhrmacher, Sabrina, Kreuzer, Karl-Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222268/
https://www.ncbi.nlm.nih.gov/pubmed/22184516
http://dx.doi.org/10.4081/hr.2010.e3
_version_ 1782217194499735552
author Erdfelder, Felix
Hertweck, Magdalena
Filipovich, Alexandra
Uhrmacher, Sabrina
Kreuzer, Karl-Anton
author_facet Erdfelder, Felix
Hertweck, Magdalena
Filipovich, Alexandra
Uhrmacher, Sabrina
Kreuzer, Karl-Anton
author_sort Erdfelder, Felix
collection PubMed
description We determined lymphoid enhancer-binding factor-1 (LEF1) mRNA expression in 112 chronic lymphocytic leukemia (CLL) samples and assessed correlations with the prognostic markers ZAP70 and CD38, Binet stages, the percentage of lymphocytes in the peripheral blood, and fibromodulin (FMOD) transcripts. The mean LEF1 relative expression ratios (RER) were 53.72 and 37.10 in ZAP70-positive and ZAP70-negative patients, respectively (P=0.004). However, we did not observe a significant difference in LEF1 expression between CD38-positive and CD38-negative patients. Moreover, patients requiring treatment showed a mean LEF1 RER of 85.61 whereas patients in recently diagnosed Binet A stage had a mean of only 22.01 (P<0.001). We also found significant correlations of LEF1 with the percentage of lymphocytes and FMOD expression. Our results suggest that high LEF1 expression is associated with poor prognosis and disease progression. Thus, LEF1 might be involved in the process of disease progression and possibly can serve as a molecular parameter for risk assessment and/or monitoring of CLL.
format Online
Article
Text
id pubmed-3222268
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-32222682011-12-19 High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia Erdfelder, Felix Hertweck, Magdalena Filipovich, Alexandra Uhrmacher, Sabrina Kreuzer, Karl-Anton Hematol Rep Article We determined lymphoid enhancer-binding factor-1 (LEF1) mRNA expression in 112 chronic lymphocytic leukemia (CLL) samples and assessed correlations with the prognostic markers ZAP70 and CD38, Binet stages, the percentage of lymphocytes in the peripheral blood, and fibromodulin (FMOD) transcripts. The mean LEF1 relative expression ratios (RER) were 53.72 and 37.10 in ZAP70-positive and ZAP70-negative patients, respectively (P=0.004). However, we did not observe a significant difference in LEF1 expression between CD38-positive and CD38-negative patients. Moreover, patients requiring treatment showed a mean LEF1 RER of 85.61 whereas patients in recently diagnosed Binet A stage had a mean of only 22.01 (P<0.001). We also found significant correlations of LEF1 with the percentage of lymphocytes and FMOD expression. Our results suggest that high LEF1 expression is associated with poor prognosis and disease progression. Thus, LEF1 might be involved in the process of disease progression and possibly can serve as a molecular parameter for risk assessment and/or monitoring of CLL. PAGEPress Publications 2010-05-06 /pmc/articles/PMC3222268/ /pubmed/22184516 http://dx.doi.org/10.4081/hr.2010.e3 Text en ©Copyright F. Erdfelder et al., 2010 This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). Licensee PAGEPress, Italy
spellingShingle Article
Erdfelder, Felix
Hertweck, Magdalena
Filipovich, Alexandra
Uhrmacher, Sabrina
Kreuzer, Karl-Anton
High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title_full High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title_fullStr High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title_full_unstemmed High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title_short High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
title_sort high lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222268/
https://www.ncbi.nlm.nih.gov/pubmed/22184516
http://dx.doi.org/10.4081/hr.2010.e3
work_keys_str_mv AT erdfelderfelix highlymphoidenhancerbindingfactor1expressionisassociatedwithdiseaseprogressionandpoorprognosisinchroniclymphocyticleukemia
AT hertweckmagdalena highlymphoidenhancerbindingfactor1expressionisassociatedwithdiseaseprogressionandpoorprognosisinchroniclymphocyticleukemia
AT filipovichalexandra highlymphoidenhancerbindingfactor1expressionisassociatedwithdiseaseprogressionandpoorprognosisinchroniclymphocyticleukemia
AT uhrmachersabrina highlymphoidenhancerbindingfactor1expressionisassociatedwithdiseaseprogressionandpoorprognosisinchroniclymphocyticleukemia
AT kreuzerkarlanton highlymphoidenhancerbindingfactor1expressionisassociatedwithdiseaseprogressionandpoorprognosisinchroniclymphocyticleukemia